IPO registrations (S-1, F-1) · Registrants
NeuroDerm Ltd.
- SEC CIK
- 1598696 · filings on EDGAR ↗
- Former names
- NeuroDerm, Ltd. (2014–2014)
- Registration
- Form F-1, first filed 2014-09-15, last 2015-07-13; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2014-11-17; declared effective 2014-11-13
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Business address
- RUHRBERG SCIENCE BUILDING, 3 PEKERIS ST., Rehovot, L3 7670203
- EDGAR entity type
- other
Offering terms
- Proposed price range
- $13.00–$16.00 per share (F-1/A filed 2014-11-07)
- Final price
- $10.00 per share, below the range (424B4 filed 2014-11-17, an initial public offering)
- Shares sold
- 4,500,000
- Gross proceeds
- $45,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol NDRM
- Lead underwriters
- Jefferies
- Syndicate
- Cowen; Oppenheimer; Roth Capital Partners
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
Filings 11
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-09-15 | F-1 | F-1 (foreign registration) | NeuroDerm, Ltd. | 0001047469-14-007634 ↗ |
| 2014-11-03 | F-1/A | F-1/A (amendment) | NeuroDerm Ltd. | 0001047469-14-008738 ↗ |
| 2014-11-07 | F-1/A | F-1/A (amendment) | NeuroDerm Ltd. | 0001047469-14-008977 ↗ |
| 2014-11-13 | EFFECT | EFFECT (declared effective) | NeuroDerm Ltd. | 9999999995-14-003351 ↗ |
| 2014-11-17 | 424B4 | 424B4 (final prospectus) | NeuroDerm Ltd. | 0001047469-14-009280 ↗ |
| 2015-07-02 | F-1 | F-1 (foreign registration) | NeuroDerm Ltd. | 0001144204-15-040908 ↗ |
| 2015-07-13 | F-1/A | F-1/A (amendment) | NeuroDerm Ltd. | 0001144204-15-042233 ↗ |
| 2015-07-15 | F-1MEF | F-1MEF (added securities) | NeuroDerm Ltd. | 0001144204-15-042756 ↗ |
| 2015-07-15 | EFFECT | EFFECT (declared effective) | NeuroDerm Ltd. | 9999999995-15-001936 ↗ |
| 2015-07-17 | 424B4 | 424B4 (final prospectus) | NeuroDerm Ltd. | 0001144204-15-042923 ↗ |
| 2016-04-18 | EFFECT | EFFECT (declared effective) | NeuroDerm Ltd. | 9999999995-16-004257 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-11-07 | F-1/A | registration statement | $13.00–$16.00 | $6.75 | 4,500,000 | $30,375,000 | Nasdaq NDRM | 4 | primary document; range, price line, shares headline, proceeds computed, cover names 4 | document ↗ |
| 2014-11-17 | 424B4 | final prospectus | $10.00 | 4,500,000 | $45,000,000 | Nasdaq NDRM | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Others with the same interests
SIC industry Pharmaceutical Preparations, L3 first:
- CANNAPOWDER, INC. L3
- Rosetta Genomics Ltd. L3
- BIOCANCELL THERAPEUTICS INC. L3
- Can-Fite BioPharma Ltd. L3
- RedHill Biopharma Ltd. L3
- KAMADA LTD L3
- MAPI - PHARMA LTD L3
- Advanced Inhalation Therapies (AIT) Ltd. L3
- Silenseed Ltd. L3
- SciSparc Ltd. L3
In other datasets, the same topic (Health) in L3:
- Form D issuer: Agada Medical Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health